RxDoctor Payments DataLook up a doctor →

James Lehmann, MD

Ophthalmology · San Antonio, TXNPI 1861432114

Payments from drug & device makers

$1,072,381in general payments, 2019–2025

Across 351 payments — averaging $3055.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$613K
  • Rxsight Inc$227K
  • Glaukos Corporation$111K
  • Avedro Inc.$83K
  • AbbVie$19K
  • Lensar, Inc.$16K
  • plus $4K from 23 others
$170,606in research payments, 2019–2025

Across 28 payments — averaging $6093.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Rxsight Inc$171K

What the payments were for

  • Consulting fees$20,95013%
  • Speaking & faculty fees$123,89576%
  • Food & beverage$9,5416%
  • Gifts$2220%
  • Other$7,4755%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,072,381 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$740,725
Medicare patients
845
Services billed
3,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate208$8,867
Difluprednate43$3,809
Tobramycin-DexamethasoneTobramycin/Dexamethasone41$2,027
Bromfenac Sodium11$1,200
ValacyclovirValacyclovir Hcl36$1,148
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat49$1,037
Latanoprost42$447
Tobramycin43$192
ErythromycinErythromycin Base19$175

Paid to pharmacies, not to this prescriber.

Other ophthalmology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →